MX2018001173A - Compuestos ciclicos utiles como moduladores del factor de necrosis tumoral (tnf) alfa. - Google Patents
Compuestos ciclicos utiles como moduladores del factor de necrosis tumoral (tnf) alfa.Info
- Publication number
- MX2018001173A MX2018001173A MX2018001173A MX2018001173A MX2018001173A MX 2018001173 A MX2018001173 A MX 2018001173A MX 2018001173 A MX2018001173 A MX 2018001173A MX 2018001173 A MX2018001173 A MX 2018001173A MX 2018001173 A MX2018001173 A MX 2018001173A
- Authority
- MX
- Mexico
- Prior art keywords
- modulators
- compounds useful
- tnf alpha
- cyclic compounds
- compounds
- Prior art date
Links
- 150000001923 cyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000004008 6 membered carbocyclic group Chemical group 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 abstract 1
- 102100040247 Tumor necrosis factor Human genes 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562200415P | 2015-08-03 | 2015-08-03 | |
| PCT/US2016/045104 WO2017023902A1 (en) | 2015-08-03 | 2016-08-02 | Cyclic compounds useful as modulators of tnf alpha |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018001173A true MX2018001173A (es) | 2018-04-24 |
Family
ID=56610045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018001173A MX2018001173A (es) | 2015-08-03 | 2016-08-02 | Compuestos ciclicos utiles como moduladores del factor de necrosis tumoral (tnf) alfa. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10335392B2 (enExample) |
| EP (1) | EP3331889B1 (enExample) |
| JP (1) | JP6811233B2 (enExample) |
| KR (1) | KR102679517B1 (enExample) |
| CN (1) | CN108137609B (enExample) |
| AU (1) | AU2016301215A1 (enExample) |
| BR (1) | BR112018001980A2 (enExample) |
| CA (1) | CA2994703A1 (enExample) |
| EA (1) | EA201890421A1 (enExample) |
| ES (1) | ES2828696T3 (enExample) |
| IL (1) | IL257159A (enExample) |
| MX (1) | MX2018001173A (enExample) |
| WO (1) | WO2017023902A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY36629A (es) | 2015-04-17 | 2016-11-30 | Abbvie Inc | Indazolonas como moduladores de la señalización de tnf |
| EP3286195A1 (en) | 2015-04-17 | 2018-02-28 | AbbVie Inc. | Indazolones as modulators of tnf signaling |
| AR104291A1 (es) | 2015-04-17 | 2017-07-12 | Abbvie Inc | Moduladores tricíclicos de la señalización por tnf |
| GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
| GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
| WO2021226208A2 (en) | 2020-05-05 | 2021-11-11 | Nuvalent, Inc. | Heteroaromatic macrocyclic ether chemotherapeutic agents |
| KR102698413B1 (ko) | 2020-05-05 | 2024-08-26 | 뉴베일런트, 아이엔씨. | 헤테로방향족 거대환식 에터 화학치료제 |
| TW202320768A (zh) | 2021-10-01 | 2023-06-01 | 美商努法倫特公司 | 雜芳族大環醚化合物之固體形式、醫藥組成物及製備 |
| KR20250051687A (ko) * | 2022-08-08 | 2025-04-17 | 메디노 파마슈티컬 테크놀로지 (주하이) 컴퍼니 리미티드 | TGF-β 억제제 화합물 및 그 사용 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5149386A (ja) * | 1974-10-28 | 1976-04-28 | Hitachi Ltd | Shuchukanshiseigyohoho |
| EP0963371B1 (en) | 1997-02-25 | 2003-05-02 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase |
| JPH11228539A (ja) * | 1997-12-03 | 1999-08-24 | Taisho Pharmaceut Co Ltd | 含窒素四環性化合物 |
| US7601846B2 (en) | 2001-06-26 | 2009-10-13 | The Regents Of The University Of California | Compounds having activity as inhibitors of apoptosis |
| CA2474850A1 (en) | 2002-01-31 | 2003-08-07 | Daiichi Pharmaceutical Co., Ltd. | Imidazo[1,2-a]pyridine derivatives |
| WO2004050035A2 (en) | 2002-12-03 | 2004-06-17 | Isis Pharmaceuticals, Inc. | Benzimidazoles and analogs thereof as antivirals |
| US20050124638A1 (en) | 2003-12-08 | 2005-06-09 | Swayze Eric E. | Benzimidazoles and analogs thereof as antivirals |
| EP2209785A1 (en) | 2007-10-05 | 2010-07-28 | S*BIO Pte Ltd | 2-morpholinylpurines as inhibitors of pi3k |
| JP2009227599A (ja) | 2008-03-21 | 2009-10-08 | Daiichi Sankyo Co Ltd | イミダゾピリダジン誘導体 |
| CN101717397B (zh) | 2008-10-09 | 2012-11-28 | 中国科学院上海药物研究所 | 一类取代吡啶并[2',1':2,3]咪唑并[4,5-c]异喹啉酮类化合物及其合成方法和用途,以及包含该类化合物的药物组合物 |
| CN102438660A (zh) | 2009-03-23 | 2012-05-02 | 美国西门子医疗解决公司 | 用于检测神经障碍的显像剂 |
| US8691187B2 (en) | 2009-03-23 | 2014-04-08 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
| WO2012148550A1 (en) | 2011-02-25 | 2012-11-01 | Myrexis, Inc. | Prodrugs of therapeutic compounds |
| EP2527344A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
| ES2689429T3 (es) | 2012-07-13 | 2018-11-14 | Ucb Biopharma Sprl | Derivados de imidazopiridina como moduladores de actividad de TNF |
| GB201212513D0 (en) | 2012-07-13 | 2012-08-29 | Ucb Pharma Sa | Therapeutic agents |
| KR101669334B1 (ko) * | 2013-09-30 | 2016-10-25 | 주식회사 엘지화학 | 헤테로환 화합물 및 이를 포함하는 유기 발광 소자 |
| GB201321738D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321743D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321746D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| US9815797B2 (en) | 2013-12-09 | 2017-11-14 | Ucb Biopharma Sprl | Fused bicyclic heteroaromatic derivatives as modulators of TNF activity |
| GB201321735D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321728D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321742D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321744D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321737D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| ES2809535T3 (es) | 2013-12-09 | 2021-03-04 | UCB Biopharma SRL | Derivados de imidazopiridina como moduladores de la actividad de TNF |
| GB201321745D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321739D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321741D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| DK3204386T3 (da) | 2014-10-06 | 2021-05-25 | Signal Pharm Llc | Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed |
| US10112944B2 (en) | 2015-03-18 | 2018-10-30 | Bristol-Myers Squibb Company | Heterocyclic compounds useful as inhibitors of TNF |
| ES2797805T3 (es) | 2015-03-18 | 2020-12-03 | Bristol Myers Squibb Co | Compuestos heterocíclicos tricíclicos sustituidos |
| ES2797685T3 (es) | 2015-03-18 | 2020-12-03 | Bristol Myers Squibb Co | Compuestos heterocíclicos tricíclicos útiles como inhibidores de TNF |
-
2016
- 2016-08-02 EA EA201890421A patent/EA201890421A1/ru unknown
- 2016-08-02 CA CA2994703A patent/CA2994703A1/en not_active Abandoned
- 2016-08-02 BR BR112018001980A patent/BR112018001980A2/pt not_active Application Discontinuation
- 2016-08-02 AU AU2016301215A patent/AU2016301215A1/en not_active Abandoned
- 2016-08-02 MX MX2018001173A patent/MX2018001173A/es unknown
- 2016-08-02 EP EP16748045.8A patent/EP3331889B1/en active Active
- 2016-08-02 JP JP2018506125A patent/JP6811233B2/ja active Active
- 2016-08-02 US US15/749,611 patent/US10335392B2/en active Active
- 2016-08-02 KR KR1020187005708A patent/KR102679517B1/ko active Active
- 2016-08-02 WO PCT/US2016/045104 patent/WO2017023902A1/en not_active Ceased
- 2016-08-02 CN CN201680057965.1A patent/CN108137609B/zh active Active
- 2016-08-02 ES ES16748045T patent/ES2828696T3/es active Active
-
2018
- 2018-01-25 IL IL257159A patent/IL257159A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180031773A (ko) | 2018-03-28 |
| US20180221344A1 (en) | 2018-08-09 |
| CA2994703A1 (en) | 2017-02-09 |
| ES2828696T3 (es) | 2021-05-27 |
| US10335392B2 (en) | 2019-07-02 |
| CN108137609A (zh) | 2018-06-08 |
| KR102679517B1 (ko) | 2024-06-27 |
| JP6811233B2 (ja) | 2021-01-13 |
| WO2017023902A1 (en) | 2017-02-09 |
| IL257159A (en) | 2018-03-29 |
| AU2016301215A1 (en) | 2018-03-22 |
| EP3331889B1 (en) | 2020-09-23 |
| JP2018525377A (ja) | 2018-09-06 |
| EA201890421A1 (ru) | 2018-07-31 |
| CN108137609B (zh) | 2021-07-16 |
| EP3331889A1 (en) | 2018-06-13 |
| BR112018001980A2 (pt) | 2018-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1252623A1 (zh) | 可用作TNFα调节剂的杂环化合物 | |
| UA122498C2 (uk) | Біциклічні похідні, спосіб їх отримання та фармацевтичні композиції, що їх містять | |
| MX2017011433A (es) | Compuestos heterociclicos triciclicos utiles como inhibidores del factor de necrosis tumoral (tnf). | |
| EA202091480A1 (ru) | Аминоиндольные соединения, пригодные в качестве ингибиторов tlr | |
| PH12017502266A1 (en) | New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| EA201790024A1 (ru) | Модуляторы toll-подобных рецепторов для лечения вич | |
| UA118680C2 (uk) | Похідні заміщеного гліоксамідом піроламіду та їхнє застосування як лікарських препаратів для лікування гепатиту в | |
| MY190243A (en) | Hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| MX380122B (es) | Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas. | |
| MD4779B1 (ro) | Compuşi aril sau heteroaril biciclici condensaţi şi utilizarea acestora ca inhibitori IRAK4 | |
| MX378435B (es) | Administración específica del sitio de un inhibidor de btk. | |
| MX2021003792A (es) | Inhibidores de benzoquinolina del transportador vesicular de monoaminas 2. | |
| MX2017011577A (es) | Compuestos heterociclicos utiles como inhibidores de factor de necrosis tumoral (tnf). | |
| GEAP201814401A (en) | Heterocyclic compounds and their use as retinoidrelated orphan receptor (ror) gamma-t inhibitors | |
| BR112018001980A2 (pt) | compostos cíclicos úteis como moduladores de tnf alfa | |
| MX374728B (es) | MODULADORES DE ROR GAMMA (RORy). | |
| EA201692480A1 (ru) | Фармацевтическая композиция | |
| MX377329B (es) | Moduladores de ror gamma (ror?). | |
| TW201613864A (en) | Novel compounds | |
| MX2017011434A (es) | Compuestos heterociclicos triciclicos sustituidos. | |
| EA201792057A1 (ru) | Конденсированные бициклические гетероарильные производные с активностью ингибиторов пролилгидроксилазы | |
| MD20170011A2 (ro) | Compuşi imidazopiridazinici | |
| MX378111B (es) | Moduladores de ror gamma (ror?). | |
| MX381129B (es) | Inhibidores de dopamina-b-hidroxilasa. | |
| IN2014DN09314A (enExample) |